Aduro Biotech Inc. (NASDAQ:ADRO)’s share price was down 4.9% on Tuesday . The stock traded as low as $12.71 and last traded at $12.71, with a volume of 88,655 shares trading hands. The stock had previously closed at $13.37.

A number of equities research analysts recently issued reports on ADRO shares. Roth Capital reaffirmed a “buy” rating and set a $46.00 target price on shares of Aduro Biotech in a research note on Friday, April 1st. FBR & Co reaffirmed an “outperform” rating and set a $30.00 target price on shares of Aduro Biotech in a research note on Monday, March 28th. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Monday, March 28th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro Biotech in a research note on Monday, May 16th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $14.00 target price (down previously from $48.00) on shares of Aduro Biotech in a research note on Tuesday, May 17th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $24.17.

The firm’s market capitalization is $820.56 million. The stock’s 50-day moving average price is $11.89 and its 200 day moving average price is $14.00.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Monday, May 2nd. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.20. On average, analysts anticipate that Aduro Biotech Inc. will post ($1.24) EPS for the current fiscal year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total transaction of $290,250.00. Following the sale, the insider now directly owns 13,939 shares in the company, valued at approximately $161,831.79. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

A hedge fund recently raised its stake in Aduro Biotech stock. Jennison Associates LLC increased its position in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned about 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.